Skip to main content

Intellia Therapeutics, Inc. (NTLA)

NASDAQ: NTLA · Delayed Price · USD
134.20
-0.01 (-0.01%)
After-hours:Oct 21, 2021 4:15 PM EDT
134.21
5.07 (3.93%)
At close: Oct 21, 4:00 PM
Market Cap9.75B
Revenue (ttm)41.81M
Net Income (ttm)-185.04M
Shares Out68.16M
EPS (ttm)-2.90
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume759,409
Open130.21
Previous Close129.14
Day's Range130.21 - 138.48
52-Week Range23.49 - 202.73
Beta2.17
AnalystsBuy
Price Target175.56 (+30.8%)
Est. Earnings DateNov 4, 2021

About NTLA

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 ...

IndustryBiotechnology
IPO DateMay 6, 2016
CEOJohn Leonard
Employees312
Stock ExchangeNASDAQ
Ticker SymbolNTLA
Full Company Profile

Financial Performance

In 2020, NTLA's revenue was $57.99 million, an increase of 34.55% compared to the previous year's $43.10 million. Losses were -$134.23 million, 34.9% more than in 2019.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is 175.56, which is an increase of 30.81% from the latest price.

Price Target
$175.56
(30.81% upside)
Analyst Consensus: Buy

News

If I Could Only Own 1 Healthcare Stock, This Is What It Would Be

Investing gets simple if you have to put all of your eggs in one basket.

7 hours ago - The Motley Fool

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for ...

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...

9 hours ago - GlobeNewsWire

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities a...

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...

1 day ago - GlobeNewsWire

Intellia Moves Into Eye Treatments With SparingVision Deal

Intellia Therapeutics Inc. ( NTLA , Financial) is following in the footsteps of several members of Big Pharma that have hooked up with smaller, specialized biotechs to develop gene therapies to treat ey...

2 days ago - GuruFocus

2 Gene-Editing Stocks to Have on Your Radar Right Now

They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.

Other symbols:VERV
4 days ago - The Motley Fool

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

A key gene-editing readout had Cathie Wood shuffling her portfolio.

Other symbols:ALLOBEAM
6 days ago - The Motley Fool

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRIS...

CAMBRIDGE, Mass. and PARIS, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics usin...

1 week ago - GlobeNewsWire

Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 202...

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...

1 week ago - GlobeNewsWire

Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients

The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) Phase 1/2 study of NTLA-2002 in hereditary angioedema (HAE). NTLA-2002 ...

2 weeks ago - Benzinga

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of H...

CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...

2 weeks ago - GlobeNewsWire

Intellia Therapeutics to Present at Chardan's 5th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/C...

3 weeks ago - GlobeNewsWire

Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients

The FDA has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) investigational new drug (IND) application for NTLA-5001. Related Content:   Intellia Shares Shoot Higher On Promising Biomarker Data Fr...

1 month ago - Benzinga

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR...

CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/C...

1 month ago - GlobeNewsWire

7 Gene Editing Stocks Promising to Change our DNA

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared fi...

1 month ago - InvestorPlace

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic Rev...

Other symbols:BEAMEDITILMN
1 month ago - InvestorPlace

Intellia Therapeutics to Present at September Healthcare Investor Conferences

CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...

1 month ago - GlobeNewsWire

New Strong Sell Stocks for August 24th

BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021

Other symbols:BGSELOXFTHMLEVL
1 month ago - Zacks Investment Research

Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today

Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. The post Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and ...

Other symbols:CRSPEDIT
1 month ago - InvestorPlace

Will Moderna's Interest Boost Gene Editing Stocks?

Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from a...

Other symbols:EDITSGMO
2 months ago - Forbes

How Are Genomics ETFs Responding to Q2 Earnings?

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

2 months ago - Zacks Investment Research

Why Shares of Intellia Therapeutics Are Jumping Today

More progress in the pipeline has investors bullish on the company's shares.

2 months ago - The Motley Fool

Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today

Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. The post Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are C...

Other symbols:CRSPEDIT
2 months ago - InvestorPlace

Why Intellia Therapeutics Shares Are Trading Higher Today

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks y...

2 months ago - Benzinga

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -65.57% and -45.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st...

2 months ago - Zacks Investment Research

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...

2 months ago - GlobeNewsWire